Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Haese

Showing results (131-140 of 214) with videos related to

Pageof 22
Sort By:
European Urology|January 18, 2006
The 2002 AJCC pT2 substages confer no prognostic information on the rate of biochemical recurrence after radical prostatectomyFelix K-H Chun, Alberto Briganti, Thierry Lebeau, et al.
BJU International|November 17, 2007
A nomogram is more accurate than a regression tree in predicting lymph node invasion in prostate cancerAlberto Briganti, Andrea Gallina, Nazareno Suardi, et al.
BJU International|December 11, 2020
Prospective validation of microseminoprotein-β added to the 4Kscore in predicting high-grade prostate cancer in an international multicentre cohortPeter E Lonergan, Emily A Vertosick, Melissa Assel, et al.
Journal of Endourology|March 22, 2008
Biopsies performed at tertiary care centers are superior to referral biopsies in predicting pathologic Gleason sumPierre I Karakiewicz, Felix K-H Chun, Andrea Gallina, et al.
European Urology Oncology|August 15, 2019
Development and Validation of a Lookup Table for the Prediction of Metastatic Prostate Cancer According to Prostatic-specific Antigen Value, Clinical Tumor Stage, and Gleason Grade GroupsFelix Preisser, Marco Bandini, Sebastiano Nazzani, et al.
The Journal of Urology|September 9, 2014
Use of phosphodiesterase type 5 inhibitors may adversely impact biochemical recurrence after radical prostatectomyUwe Michl, Frederike Molfenter, Markus Graefen, et al.
Urology|August 12, 2008
Assessment of biochemical recurrence rate in patients with pathologically confirmed insignificant prostate cancerUmberto Capitanio, Sasha Ahyai, Markus Graefen, et al.
European Urology|August 21, 2014
Preoperative Prostate-specific Antigen Isoform p2PSA and Its Derivatives, %p2PSA and Prostate Health Index, Predict Pathologic Outcomes in Patients Undergoing Radical Prostatectomy for Prostate Cancer: Results from a Multicentric European Prospective StudyNicola Fossati, Nicolò Maria Buffi, Alexander Haese, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 17, 2008
Clinical significance of p53 alterations in surgically treated prostate cancersThorsten Schlomm, Liv Iwers, Patrick Kirstein, et al.
Current Oncology (Toronto, Ont.)|April 21, 2022
Concordance between Preoperative mpMRI and Pathological Stage and Its Influence on Nerve-Sparing Surgery in Patients with High-Risk Prostate CancerClara Humke, Benedikt Hoeh, Felix Preisser, et al.
Pageof 22

Showing results (131-140 of 214) with videos related to

Sort By:
Pageof 22
European Urology|January 18, 2006
The 2002 AJCC pT2 substages confer no prognostic information on the rate of biochemical recurrence after radical prostatectomyFelix K-H Chun, Alberto Briganti, Thierry Lebeau, et al.
BJU International|November 17, 2007
A nomogram is more accurate than a regression tree in predicting lymph node invasion in prostate cancerAlberto Briganti, Andrea Gallina, Nazareno Suardi, et al.
BJU International|December 11, 2020
Prospective validation of microseminoprotein-β added to the 4Kscore in predicting high-grade prostate cancer in an international multicentre cohortPeter E Lonergan, Emily A Vertosick, Melissa Assel, et al.
Journal of Endourology|March 22, 2008
Biopsies performed at tertiary care centers are superior to referral biopsies in predicting pathologic Gleason sumPierre I Karakiewicz, Felix K-H Chun, Andrea Gallina, et al.
European Urology Oncology|August 15, 2019
Development and Validation of a Lookup Table for the Prediction of Metastatic Prostate Cancer According to Prostatic-specific Antigen Value, Clinical Tumor Stage, and Gleason Grade GroupsFelix Preisser, Marco Bandini, Sebastiano Nazzani, et al.
The Journal of Urology|September 9, 2014
Use of phosphodiesterase type 5 inhibitors may adversely impact biochemical recurrence after radical prostatectomyUwe Michl, Frederike Molfenter, Markus Graefen, et al.
Urology|August 12, 2008
Assessment of biochemical recurrence rate in patients with pathologically confirmed insignificant prostate cancerUmberto Capitanio, Sasha Ahyai, Markus Graefen, et al.
European Urology|August 21, 2014
Preoperative Prostate-specific Antigen Isoform p2PSA and Its Derivatives, %p2PSA and Prostate Health Index, Predict Pathologic Outcomes in Patients Undergoing Radical Prostatectomy for Prostate Cancer: Results from a Multicentric European Prospective StudyNicola Fossati, Nicolò Maria Buffi, Alexander Haese, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 17, 2008
Clinical significance of p53 alterations in surgically treated prostate cancersThorsten Schlomm, Liv Iwers, Patrick Kirstein, et al.
Current Oncology (Toronto, Ont.)|April 21, 2022
Concordance between Preoperative mpMRI and Pathological Stage and Its Influence on Nerve-Sparing Surgery in Patients with High-Risk Prostate CancerClara Humke, Benedikt Hoeh, Felix Preisser, et al.
Pageof 22